Literature DB >> 15103311

Prevalence and determinants of undertreatment of hypertension in the Netherlands.

H Schelleman1, O H Klungel, D Kromhout, A de Boer, B H Ch Stricker, W M M Verschuren.   

Abstract

The objective of this study was to determine the prevalence, treatment, and control of hypertension, and the determinants of undertreatment in the Dutch population. The study design was cross-sectional. A population-based survey on cardiovascular disease risk factors in the Netherlands from 1996 to 2002 was the setting of the study. A total of 10 820 men and women, aged 30-59 years, were included in the study. The main outcome measures of the study were: Prevalence of hypertension, treatment, and control of hypertension and determinants of undertreatment of hypertension. Hypertension was defined as: systolic blood pressure (SBP) > or =140 mmHg and/or diastolic blood pressure (DBP) > or =90 mmHg, and/or the use of antihypertensive medication. Treated and controlled hypertension was defined as SBP <140 mmHg and DBP <90 mmHg. Multivariate logistic regression was used to assess the determinants of undertreatment. The prevalence of hypertension in men was 21.4% and in women 14.9%, and 17.9% of the hypertensive men and 38.5% of the hypertensive women were receiving antihypertensive medication. Of the untreated hypertensives, 21.9% of the men and 13.6% of the women were eligible for treatment with antihypertensive medication according to Dutch guidelines. Female gender and the use of cholesterol-lowering medication were associated with an increased chance of being treated. Subjects who were physically active, on a low salt diet, and current smokers had an increased chance of being untreated. Taking cholesterol-lowering medication and no asthma or allergy were factors associated with better control of blood pressure. In conclusion, a considerable proportion of hypertensives were untreated and uncontrolled. Therefore, the detection and control of hypertension in the Netherlands needs to improve. Several groups of hypertensives were identified that need additional care and attention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15103311     DOI: 10.1038/sj.jhh.1001672

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

1.  Revised guidelines for cardiovascular risk management - time to stop medication? A practice-based intervention study.

Authors:  Huug J van Duijn; Janneke N Belo; Jeanet W Blom; Irvine D Velberg; Willem J J Assendelft
Journal:  Br J Gen Pract       Date:  2011-06       Impact factor: 5.386

2.  Hypertension risk in idiopathic hyperCKemia.

Authors:  Lizzy M Brewster; Sjoerd van Bree; Jaap C Reijneveld; Nicolette C Notermans; W M Monique Verschuren; Joseph F Clark; Gert A van Montfrans; Marianne de Visser
Journal:  J Neurol       Date:  2008-01-22       Impact factor: 4.849

Review 3.  Genetic variants of the Renin Angiotensin system: effects on atherosclerosis in experimental models and humans.

Authors:  Alan Daugherty; Aruna Poduri; Xiaofeng Chen; Hong Lu; Lisa A Cassis
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

4.  Effect of a Digitally-Enabled, Preventive Health Program on Blood Pressure in an Adult, Dutch General Population Cohort: An Observational Pilot Study.

Authors:  José Castela Forte; Pytrik Folkertsma; Rahul Gannamani; Sridhar Kumaraswamy; Sipko van Dam; Jan Hoogsteen
Journal:  Int J Environ Res Public Health       Date:  2022-03-31       Impact factor: 3.390

Review 5.  The Diagnosis and Management of Cardiometabolic Risk and Cardiometabolic Syndrome after Spinal Cord Injury.

Authors:  Gary J Farkas; Adam M Burton; David W McMillan; Alicia Sneij; David R Gater
Journal:  J Pers Med       Date:  2022-06-30

6.  Ethnic differences in the effect of environmental stressors on blood pressure and hypertension in the Netherlands.

Authors:  Charles Agyemang; Carolien van Hooijdonk; Wanda Wendel-Vos; Joanne K Ujcic-Voortman; Ellen Lindeman; Karien Stronks; Mariel Droomers
Journal:  BMC Public Health       Date:  2007-06-23       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.